4-Oxospiro[benzopyran-2,4'-piperidines] as class III antiarrhythmic agents. Pharmacological studies on 3,4-dihydro-1'-[2-(benzofurazan-5-yl)- ethyl]-6-methanesulfonamidospiro[(2H)-1-benzopyran-2,4'-piperidin]-4-on e (L-691,121). 1992

J M Elliott, and H G Selnick, and D A Claremon, and J J Baldwin, and S A Buhrow, and J W Butcher, and C N Habecker, and S W King, and J J Lynch, and B T Phillips
Department of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486.

UI MeSH Term Description Entries
D010881 Piperidones A family of saturated heterocyclic organic compounds which contain one nitrogen atom and a carbonyl group in the ring structure. Piperidone
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D013141 Spiro Compounds Cyclic compounds that include two rings which share a single atom (usually a carbon). The simplest example of this type of compound is Spiro[2.2]pentane, which looks like a bow tie. Compounds, Spiro
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

J M Elliott, and H G Selnick, and D A Claremon, and J J Baldwin, and S A Buhrow, and J W Butcher, and C N Habecker, and S W King, and J J Lynch, and B T Phillips
May 1993, The Journal of pharmacology and experimental therapeutics,
J M Elliott, and H G Selnick, and D A Claremon, and J J Baldwin, and S A Buhrow, and J W Butcher, and C N Habecker, and S W King, and J J Lynch, and B T Phillips
May 1993, Journal of pharmaceutical sciences,
J M Elliott, and H G Selnick, and D A Claremon, and J J Baldwin, and S A Buhrow, and J W Butcher, and C N Habecker, and S W King, and J J Lynch, and B T Phillips
April 2011, Acta crystallographica. Section E, Structure reports online,
J M Elliott, and H G Selnick, and D A Claremon, and J J Baldwin, and S A Buhrow, and J W Butcher, and C N Habecker, and S W King, and J J Lynch, and B T Phillips
January 1999, Bioorganic & medicinal chemistry letters,
J M Elliott, and H G Selnick, and D A Claremon, and J J Baldwin, and S A Buhrow, and J W Butcher, and C N Habecker, and S W King, and J J Lynch, and B T Phillips
July 2012, Acta crystallographica. Section E, Structure reports online,
J M Elliott, and H G Selnick, and D A Claremon, and J J Baldwin, and S A Buhrow, and J W Butcher, and C N Habecker, and S W King, and J J Lynch, and B T Phillips
July 2011, Acta crystallographica. Section E, Structure reports online,
J M Elliott, and H G Selnick, and D A Claremon, and J J Baldwin, and S A Buhrow, and J W Butcher, and C N Habecker, and S W King, and J J Lynch, and B T Phillips
August 2010, Acta crystallographica. Section E, Structure reports online,
J M Elliott, and H G Selnick, and D A Claremon, and J J Baldwin, and S A Buhrow, and J W Butcher, and C N Habecker, and S W King, and J J Lynch, and B T Phillips
September 2011, Acta crystallographica. Section E, Structure reports online,
J M Elliott, and H G Selnick, and D A Claremon, and J J Baldwin, and S A Buhrow, and J W Butcher, and C N Habecker, and S W King, and J J Lynch, and B T Phillips
July 2011, Acta crystallographica. Section E, Structure reports online,
J M Elliott, and H G Selnick, and D A Claremon, and J J Baldwin, and S A Buhrow, and J W Butcher, and C N Habecker, and S W King, and J J Lynch, and B T Phillips
August 1989, Journal of medicinal chemistry,
Copied contents to your clipboard!